The FDA's Cardiovascular and Renal Drugs Advisory Committee will hold a public meeting on July 18 at the Holiday Inn in Bethesda, Md, to consider the following applications:
(1) a proposed claim of comparative effectiveness of candesartan cilexetil and losartan in hypertension and (2) approval of pravastatin sodium/aspirin copackaged product for long-term management of cardiovascular disease. The next day the committee will consider the application for the approval of omapatrilat for treatment of hypertension. For additional information call (800) 741-8138, ext 12533.
Crawford, Jr LM. Meetings on Drug Applications. JAMA. 2002;288(1):36. doi:10.1001/jama.288.1.36-JFD20007-4-1